Ulcerative Colitis

Clinical Trials

Below is a list of Ulcerative Colitis clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Abatacept for the treatment of subjects with active moderate to severe Ulcerative Colitis
The purpose of this study is to see if the investigational use of abatacept is better than placebo (inactive substance) for the treatment of active Ulcerative Colitis. Abatacept was approved by the United States Food and Drug Administration (FDA) in December 2005 for the treatment of rheumatoid arthritis in the United States and in June 2006 in Canada. The use of abatacept remains investigational for other diseases. An investigational use in one that is not yet approved by the regulatory authorities such as the FDA.

A second purpose of this study is to evaluate the safety (possible side effects) of abatacept in patients with Ulcerative Colitis.
Read more

Adalimumab for the treatment of subjects with active moderate to severe Ulcerative Colitis
This study is being done to evaluate the safety and effectiveness of adalimumab for treatment and maintenance of moderately to severely active ulcerative colitis. This study will also look at how the drug is distributed in the body over time.

Adalimumab is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or by regulatory authorities in other countries outside of the United States.

Adalimumab is made in the laboratory and is identical to a natural human antibody (a small protein made by blood cells in response to a foreign substance). Adalimumab is believed to work by blocking the inflammatory process which helps to relieve the signs and symptoms of ulcerative colitis.

It is believed that Adalimumab may help subjects with ulcerative colitis who have not had complete relief of their symptoms with currently available medications.
Read more

Adalimumab for the treatment of subjects with active moderate to severe Ulcerative Colitis who have not received anti-TNF therapy in the past
This study is being done to evaluate the safety and effectiveness of Adalimumab for treatment of moderately to severely active ulcerative colitis.

Adalimumab is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or by regulatory authorities in other countries outside of the United States.

Adalimumab is made in the laboratory and is identical to a natural human antibody (a small protein made by blood cells in response to a foreign substance). Adalimumab is believed to work by blocking the inflammatory process which helps to relieve the signs and symptoms of ulcerative colitis.

It is believed that Adalimumab may help subjects with ulcerative colitis who have not had complete relief of their symptoms with currently available medications.
Read more